BeyondSpring Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
BeyondSpring Inc. (BYSI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $20.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-25
- BeyondSpring Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $20.00K, a 65.52% decline from fiscal 2023.
- BeyondSpring Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $58.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $20.00K 10-K · filed 2026-03-25 |
| 2023-12-31 | $58.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | -$812.00K 20-F · filed 2023-04-18 |
| 2021-12-31 | $788.00K 20-F · filed 2023-04-18 |
| 2020-12-31 | $688.00K 20-F · filed 2023-04-18 |
| 2019-12-31 | $5.23M 20-F · filed 2022-04-14 |
| 2018-12-31 | $880.00K 20-F · filed 2021-04-30 |
| 2017-12-31 | $25.30M 20-F · filed 2020-04-30 |
| 2016-12-31 | $152.00K 20-F · filed 2019-04-30 |
| 2015-12-31 | $351.00K 20-F · filed 2018-04-03 |
| 2014-12-31 | $240.00K 20-F · filed 2017-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |